Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DESVENLAFAXINE Cause Prostatic specific antigen increased? 6 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Prostatic specific antigen increased have been filed in association with DESVENLAFAXINE (Desvenlafaxine Succinate). This represents 0.1% of all adverse event reports for DESVENLAFAXINE.

6
Reports of Prostatic specific antigen increased with DESVENLAFAXINE
0.1%
of all DESVENLAFAXINE reports
0
Deaths
0
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From DESVENLAFAXINE?

Of the 6 reports.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DESVENLAFAXINE. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does DESVENLAFAXINE Cause?

Drug ineffective (1,576) Anxiety (679) Feeling abnormal (671) Dizziness (605) Nausea (575) Headache (548) Depression (542) Withdrawal syndrome (530) Malaise (512) Insomnia (428)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which DESVENLAFAXINE Alternatives Have Lower Prostatic specific antigen increased Risk?

DESVENLAFAXINE vs DETROL DESVENLAFAXINE vs DEUCRAVACITINIB DESVENLAFAXINE vs DEUTETRABENAZINE DESVENLAFAXINE vs DEUTIVACAFTOR\TEZACAFTOR\VANZACAFTOR DESVENLAFAXINE vs DEVICE

Related Pages

DESVENLAFAXINE Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased DESVENLAFAXINE Demographics